A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) No significant financial relationships to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results